Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30213072 | 1.00 | ALOX15 (0.59) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| SCHEMBL107292 | 0.91 | MAPT (0.63) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| SCHEMBL11811815 | 0.89 | ALOX15 (0.69) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| SCHEMBL7279998 | 0.83 | ADRB2 (0.79) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| SCHEMBL7283172 | 0.83 | ADRB2 (0.74) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| SCHEMBL5127071 | 0.81 | ALOX15 (0.74) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| Bromide SCHEMBL7281386 | 0.81 | ADRB2 (0.77) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| Bromide SCHEMBL7281191 | 0.81 | ADRB2 (0.72) | ALOX15IGF1RKDM4EMAPK1LMNA | |
| SCHEMBL30213077 | 0.81 | BCHE (0.67) | ALOX15KDM4ELMNACA1CA2 | |
| SCHEMBL1719403 | 0.81 | BCHE (0.67) | ALOX15KDM4ELMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280535-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-09-08 | — | — | US | disclosed |
| US-11090313-B2 | Methods for inhibiting muscle atrophy | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-10668087-B2 | Methods for inhibiting muscle atrophy | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200061083-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190300892-A1 | CONSTRUCTS AND METHODS FOR BIOSYNTHESIS OF GALANTHAMINE | DONALD DANFORTH PLANT SCIENCE CENTER | 2019-10-03 | — | — | US | disclosed |
| US-20190105333-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-04-11 | — | — | US | disclosed |
| US-20160243132-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-08-25 | — | — | US | disclosed |
| US-9295664-B2 | Methods for lowering blood glucose | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140228333-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2012170546-A1 | METHODS OF INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-12-13 | — | — | WO | disclosed |
| US-7432228-B2 | Inhibitor against biosynthesis of abscisic acid | RIKEN (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7098365-B2 | Abscisic acid biosynthesis inhibitor | RIKEN (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20060148650-A1 | Inhibitor against biosynthesis of abscisic acid | RIKEN (JP) | 2006-07-06 | — | — | US | disclosed |
| US-20050014651-A1 | Abscisic acid biosynthesis inhibitor | RIKEN (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1439165-A1 | ABSCISIC ACID BIOSYNTHESIS INHIBITOR | Riken (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243132-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | CPT1B, MYOF, TNNC1 | ALOX15 2890/4885IGF1R 2301/4885KDM4E 1135/4885 |
| US-11090313-B2 | Methods for inhibiting muscle atrophy | MYOF, PYGM, MTPN | ALOX15 2563/4885IGF1R 896/4885KDM4E 1989/4885 |
| US-20060148650-A1 | Inhibitor against biosynthesis of abscisic acid | COASY, BLVRB, ME1 | ALOX15 1534/4885IGF1R 1630/4885KDM4E 1546/4885 |
| US-20200061083-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | MYOF, PYGM, MTPN | ALOX15 2563/4885IGF1R 896/4885KDM4E 1989/4885 |
| US-20140228333-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | CPT1B, MYOF, TNNC1 | ALOX15 2890/4885IGF1R 2301/4885KDM4E 1135/4885 |
| US-20220280535-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | MYOF, PYGM, MTPN | ALOX15 2563/4885IGF1R 896/4885KDM4E 1989/4885 |
| US-10668087-B2 | Methods for inhibiting muscle atrophy | CPT1B, MYOF, TNNC1 | ALOX15 2890/4885IGF1R 2301/4885KDM4E 1135/4885 |
| US-20050014651-A1 | Abscisic acid biosynthesis inhibitor | COASY, BLVRB, ME1 | ALOX15 1797/4885IGF1R 1461/4885KDM4E 1581/4885 |
| US-20190105333-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | CPT1B, MYOF, TNNC1 | ALOX15 2890/4885IGF1R 2301/4885KDM4E 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.